<DOC>
	<DOCNO>NCT00527917</DOCNO>
	<brief_summary>This pilot clinical investigation . Patients meet eligibility criterion provide sign informed consent randomize receive either active product ( Uracyst® ) placebo intravesically via bladder catheter weekly 6 week , follow 6 week follow-up period .</brief_summary>
	<brief_title>A Pilot Clinical Investigation Efficacy Safety Uracyst® Versus Placebo Patients With Interstitial Cystitis/Painful Bladder Syndrome .</brief_title>
	<detailed_description />
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<criteria>Are female male patient 18 year old Have previously diagnose IC/PBS . Are willing provide inform consent Available duration study include treatment followup ( 12 week ) Pregnant lactate female . Are currently previously receive investigational drug within thirty ( 30 ) day screen . Previous therapy IC/PBS Have medical condition/disease could interfere patient compliance interfere interpretation study result . Are unable unwilling comply protocol requirement Are unable read , understand , provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>IC/PBS</keyword>
	<keyword>Interstitial Cystitis/Painful Bladder Syndrome</keyword>
</DOC>